Normal Pressure Hydrocephalus Clinical Trial
Official title:
Acetazolamide for Treating NPH in Shunt-candidates Patients: an Open Label Feasibility Trial
Normal pressure hydrocephalus (NPH) consists of a triad of gait disturbance, cognitive
deterioration, and urinary incontinence and is characterized by enlarged cerebral ventricles.
Current treatment recommendations are based on surgical diversion of Cerebrospinal fluid
(CSF), by a ventriculoperitoneal shunt. When patients are appropriately selected, shunting
for NPH has a sustained effect in one-half to two-thirds of patients with a reasonable
complication rate. However, evidence regarding the efficacy of shunt surgery consists largely
of observational studies with relatively short-term follow-up.
With regards to the adverse effects of shunting, even though decreased substantially in
recent years, shunt complications are still common. Recent studies report ten to twenty-two
percent of serious adverse effects following shunt surgery, mainly subdural hematoma (SDH)
requiring surgery, infection, and cerebral infarction or hemorrhage. Most complication occur
in the first year after the procedure. Many others suffer from adverse events that considered
non-serious, such as postural headache and asymptomatic SDH.
Since shunt complications are common and potentially severe, there is a need for a better way
to identify those patients that will likely benefit from shunting, and find alternative
treatments for those unwilling or unable to withstand surgery.
Acetazolamide has been shown to reduce the production of CSF in clinical cases of raised
intracranial pressure. It is considered the drug of choice for the treatment of idiopathic
intracranial hypertension (pseudotumor cerebri). Intuitively, acetazolamide can be effective
for the treatment of NPH by reducing the volume of CSF in the brain, and serve as a medical
alternative to shunting. Few case reports and small series demonstrated improvement in MRI
abnormalities in NPH-patients after administrating the medication.
This open-label study will examine the feasibility and effectiveness of acetazolamide in
NPH-diagnosed patients who are shunt-candidates. Patients will be treated from time of
diagnosis, and gait and cognition will be evaluated after 2-6 weeks. This trial would
possibly pave the way to a larger randomized placebo-controlled trials, and perhaps offer a
medical alternative to surgery for elderly patients and for patients for which operation is
contraindicated.
Status | Recruiting |
Enrollment | 15 |
Est. completion date | December 2019 |
Est. primary completion date | December 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years and older |
Eligibility |
Inclusion Criteria: Included will be subjects with a probable diagnosis of NPH. The diagnosis will be based primarily on presence of gait impairment plus at least one other impairment in urinary symptoms, cognition impairment or both. 1. Are 50 years old or older. 2. Patients who meet the criteria for NPH based on: - A typical personal history. - A typical brain imaging on head CT or MRI. - Normal lumbar puncture findings excluding other conditions. - Exclusion of other more likely diagnosis. 3. Patients who underwent large-volume spinal tap and subsequently improved clinically by at least 10% in gait function or cognition. Exclusion Criteria: - Cirrhosis or marked liver disease or dysfunction. - Severe renal disease or dysfunction. - Acidosis. - Hypersensitivity to acetazolamide, sulfonamides, or any component of the formulation. - Decreased sodium and/or potassium levels. - Adrenocortical insufficiency. - Patients with cognitive impairment who will not be able to give informed consent. |
Country | Name | City | State |
---|---|---|---|
Israel | Rabin Medical Center | Petah Tikva |
Lead Sponsor | Collaborator |
---|---|
Rabin Medical Center |
Israel,
Alperin N, Oliu CJ, Bagci AM, Lee SH, Kovanlikaya I, Adams D, Katzen H, Ivkovic M, Heier L, Relkin N. Low-dose acetazolamide reverses periventricular white matter hyperintensities in iNPH. Neurology. 2014 Apr 15;82(15):1347-51. doi: 10.1212/WNL.0000000000000313. Epub 2014 Mar 14. — View Citation
Esmonde T, Cooke S. Shunting for normal pressure hydrocephalus (NPH). Cochrane Database Syst Rev. 2002;(3):CD003157. Review. — View Citation
Halperin JJ, Kurlan R, Schwalb JM, Cusimano MD, Gronseth G, Gloss D. Practice guideline: Idiopathic normal pressure hydrocephalus: Response to shunting and predictors of response: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2015 Dec 8;85(23):2063-71. doi: 10.1212/WNL.0000000000002193. Review. Erratum in: Neurology. 2016 Feb 23;86(8):793. — View Citation
Ivkovic M, Reiss-Zimmermann M, Katzen H, Preuss M, Kovanlikaya I, Heier L, Alperin N, Hoffmann KT, Relkin N. MRI assessment of the effects of acetazolamide and external lumbar drainage in idiopathic normal pressure hydrocephalus. Fluids Barriers CNS. 2015 Apr 2;12:9. doi: 10.1186/s12987-015-0004-z. — View Citation
Jaraj D, Rabiei K, Marlow T, Jensen C, Skoog I, Wikkelsø C. Prevalence of idiopathic normal-pressure hydrocephalus. Neurology. 2014 Apr 22;82(16):1449-54. doi: 10.1212/WNL.0000000000000342. Epub 2014 Mar 28. — View Citation
Kazui H, Miyajima M, Mori E, Ishikawa M; SINPHONI-2 Investigators. Lumboperitoneal shunt surgery for idiopathic normal pressure hydrocephalus (SINPHONI-2): an open-label randomised trial. Lancet Neurol. 2015 Jun;14(6):585-94. doi: 10.1016/S1474-4422(15)00046-0. Epub 2015 Apr 28. — View Citation
Klassen BT, Ahlskog JE. Normal pressure hydrocephalus: how often does the diagnosis hold water? Neurology. 2011 Sep 20;77(12):1119-25. doi: 10.1212/WNL.0b013e31822f02f5. Epub 2011 Aug 17. — View Citation
Kuriyama N, Miyajima M, Nakajima M, Kurosawa M, Fukushima W, Watanabe Y, Ozaki E, Hirota Y, Tamakoshi A, Mori E, Kato T, Tokuda T, Urae A, Arai H. Nationwide hospital-based survey of idiopathic normal pressure hydrocephalus in Japan: Epidemiological and clinical characteristics. Brain Behav. 2017 Jan 27;7(3):e00635. doi: 10.1002/brb3.635. eCollection 2017 Mar. — View Citation
ten Hove MW, Friedman DI, Patel AD, Irrcher I, Wall M, McDermott MP; NORDIC Idiopathic Intracranial Hypertension Study Group. Safety and Tolerability of Acetazolamide in the Idiopathic Intracranial Hypertension Treatment Trial. J Neuroophthalmol. 2016 Mar;36(1):13-9. doi: 10.1097/WNO.0000000000000322. — View Citation
Tisell M, Tullberg M, Hellström P, Edsbagge M, Högfeldt M, Wikkelsö C. Shunt surgery in patients with hydrocephalus and white matter changes. J Neurosurg. 2011 May;114(5):1432-8. doi: 10.3171/2010.11.JNS10967. Epub 2011 Jan 14. — View Citation
Toma AK, Papadopoulos MC, Stapleton S, Kitchen ND, Watkins LD. Systematic review of the outcome of shunt surgery in idiopathic normal-pressure hydrocephalus. Acta Neurochir (Wien). 2013 Oct;155(10):1977-80. doi: 10.1007/s00701-013-1835-5. Epub 2013 Aug 23. Review. — View Citation
* Note: There are 11 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | adverse effects | All adverse effects that may be attributed to the treatment will be recorded | week 2-6 | |
Primary | Change from Baseline Gait | Change from Baseline gait will be evaluated by the neurosurgery department's physiotherapist, using the timed-up-and-go (TUG) test (measured in seconds, higher values represent a worse outcome). Patients will be evaluated at baseline (before treatment is started) and again before surgery (4 weeks later). |
Baseline, week 4 | |
Primary | Change from Baseline Balance | Change from Baseline balance will be evaluated by the neurosurgery department's physiotherapist, using the TINETTI balance assessment score. (0-28 scale, higher values represent a better outcome). Patients will be evaluated at baseline (before treatment is started) and again before surgery (4 weeks later). |
Baseline, week 4 | |
Secondary | Change from Baseline concentration function | concentration function will be evaluated by the neurosurgery department's neuropsychologist using the color trial test (seconds, higher values represent a worse outcome). Patients will be evaluated at baseline (before treatment is started) and again before surgery (4 weeks later). |
Baseline, week 4 | |
Secondary | Change from Baseline visuospatial function | visuospatial function will be evaluated by the neurosurgery department's neuropsychologist using the clock drawing test (0-10 scale, higher values represent a better outcome). Patients will be evaluated at baseline (before treatment is started) and again before surgery (4 weeks later). |
Baseline, week 4 | |
Secondary | Change from Baseline verbal fluency | verbal fluency will be evaluated by the neurosurgery department's neuropsychologist using the verbal fluency test (Controlled Oral Word Association Test, number of words in one minute, higher values represent a better outcome). Patients will be evaluated at baseline (before treatment is started) and again before surgery (4 weeks later). |
Baseline, week 4 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00149721 -
Anterior Pituitary Function in Patients With Hydrocephalus
|
N/A | |
Completed |
NCT00196196 -
A Precision and Accuracy Study of the Codman Valve Position Verification (VPV) System.
|
Phase 3 | |
Not yet recruiting |
NCT05562596 -
Normal Pressure Hydrocephalus Biomarkers Investigation
|
||
Completed |
NCT00233701 -
Normal Pressure Hydrocephalus (NPH) Registry
|
Phase 4 | |
Unknown status |
NCT00874198 -
European Study on Prediction of Outcome in Patients With Idiopathic Normal Pressure Hydrocephalus
|
N/A | |
Withdrawn |
NCT00793416 -
ShuntCheck Accuracy in Detecting Shunt Obstruction Normal Pressure Hydrocephalus (NPH) Patients
|
Phase 4 | |
Recruiting |
NCT05910944 -
European Study of Prodromal iNPH
|
||
Active, not recruiting |
NCT01909960 -
Flow MRI in Normal Pressure Hydrocephalus
|
N/A | |
Completed |
NCT02016352 -
Cerebrospinal Fluid Proteome in Hydrocephalus
|
N/A | |
Terminated |
NCT01092546 -
Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure Hydrocephalus
|
Phase 3 | |
Terminated |
NCT00613886 -
Factors Predicting Response to Shunting in Normal Pressure Hydrocephalus
|
N/A | |
Completed |
NCT01815775 -
Predictive Value of Flow MRI in Normal Pressure Hydrocephalus Surgery
|
Phase 0 | |
Recruiting |
NCT03877107 -
Effect of Depletive Lumbar Puncture on Lower Urinary Tract Dysfunction in iNPH
|
N/A | |
Enrolling by invitation |
NCT03269201 -
Brain Network Activation in Patients With Movement Disorders
|
||
Recruiting |
NCT03245138 -
Endoscopic Third Ventriculostomy Versus Ventriculo-peritoneal Shunting in Idiopathic Normal Pressure Hydrocephalus
|
N/A | |
Terminated |
NCT00727142 -
Conservative Versus Surgical Management of Idiopathic Normal Pressure Hydrocephalus (INPH)
|
N/A | |
Recruiting |
NCT04471740 -
Normal Pressure Hydrocephalus and Sleep Apnea
|
N/A | |
Completed |
NCT01798641 -
A Randomized Cross-over Study for Normal Pressure Hydrocephalus
|
N/A | |
Recruiting |
NCT01618500 -
Computerised Testing of Cognitive Response to Cerebrospinal Fluid Shunting in Idiopathic Normal Pressure Hydrocephalus
|
N/A | |
Completed |
NCT00600795 -
Prognostic Value of Transforming Growth Factor-Beta 1 in Normal Pressure Hydrocephalus
|
N/A |